This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

81/100

✓ Peer-reviewed alzhub usefulness score 81 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Importance Modifiable risk factors are hypothesized to account for 30% to 40% of dementia; yet, few trials have demonstrated that risk-reduction interventions, especially multidomain, are efficacious. A total of 172 adults at elevated risk for dementia (age 70-89 years and with ≥2 of 8 targeted risk factors) were recruited from primary care clinics associated with Kaiser Permanente Washington. Results The 172 total participants had a mean (SD) age of 75.7 (4.8) years, and 108 (62.8%) were women. After 2 years, compared with the 90 participants in the control group, the 82 participants assigned to intervention demonstrated larger improvements in the composite cognitive score (ATE of SD, 0.14; 95% CI, 0.03-0.25; P = .02; a 74% improvement compared with the change in the control group), better composite risk factor score (ATE of SD, 0.11; 95% CI, 0.01-0.20; P = .03), and improved QOL (ATE, 0.81 points; 95% CI, -0.21 to 1.84; P = .12).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Yaffe, K., Vittinghoff, E., Dublin, S., Peltz, C. B., Fleckenstein, L. E., Rosenberg, D. E., et al. (2024). Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults: The SMARRT Randomized Clinical Trial. JAMA internal medicine. https://doi.org/10.1001/jamainternmed.2023.6279

Vancouver

Yaffe K, Vittinghoff E, Dublin S, Peltz CB, Fleckenstein LE, Rosenberg DE, et al. Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults: The SMARRT Randomized Clinical Trial. JAMA internal medicine. 2024. doi:10.1001/jamainternmed.2023.6279. PMID: 38010725.

BibTeX

@article{yaffe2024-38010725,
  author  = {Yaffe, K. and Vittinghoff, E. and Dublin, S. and Peltz, C. B. and Fleckenstein, L. E. and Rosenberg, D. E. and Barnes, D. E. and Balderson, B. H. and others},
  title   = {{Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults: The SMARRT Randomized Clinical Trial}},
  journal = {JAMA internal medicine},
  year    = {2024},
  doi     = {10.1001/jamainternmed.2023.6279},
  pmid    = {38010725},
  url     = {https://doi.org/10.1001/jamainternmed.2023.6279}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Importance Modifiable risk factors are hypothesized to account for 30% to 40% of dementia; yet, few trials have demonstrated that risk-reduction interventions, especially multidomain, are efficacious.
A total of 172 adults at elevated risk for dementia (age 70-89 years and with ≥2 of 8 targeted risk factors) were recruited from primary care clinics associated with Kaiser Permanente Washington.
Results The 172 total participants had a mean (SD) age of 75.7 (4.8) years, and 108 (62.8%) were women.
After 2 years, compared with the 90 participants in the control group, the 82 participants assigned to intervention demonstrated larger improvements in the composite cognitive score (ATE of SD, 0.14; 95% CI, 0.03-0.25; P = .02; a 74% improvement compared with the change in the control group), better composite risk factor score (ATE of SD, 0.11; 95% CI, 0.01-0.20; P = .03), and improved QOL (ATE, 0.81 points; 95% CI, -0.21 to 1.84; P = .12).

Why it matters

In this trial of 172 older adults at elevated dementia risk, those assigned to personalized risk-reduction strategies showed larger improvements in a composite cognitive score and a better composite risk factor score after two years than the control group. This suggests multidomain risk-reduction may help cognition in people with risk factors, but it does not show that Alzheimer's disease is cured or prevented.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Participants172
Effect size62.8%
Evidence strengthHigh

How this study scored 81/100

Published in a leading specialty journal, and it is a randomised controlled trial.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA internal medicine)
Journal's citation record	3 / 4	JAMA Internal Medicine: journal h-index 258 (OpenAlex, 2026-10-29)
Study design	11 / 12	A randomised controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	2 / 4	172 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	1 / 2	Randomised (as stated in the record)
Times cited	5 / 7	Cited 126 times (OpenAlex, 2026-10-10)
Citations per year	4 / 5	31.5 citations a year over 4 year(s) since 2024
Impact for its field and year	5 / 6	Cited 22.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 26 other studies in this library
Still being cited	3 / 4	Cited 126 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Eric B. Larson: h-index 105 (OpenAlex, whole career)
Institution's track record	3 / 3	University of Washington: institution h-index 3,540 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 38010725)
Free to read	0 / 2	Behind a paywall — scores zero
Total	81 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

26 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments

Also tagged “controlled”

1,116 studies in the library carry the topic tag “controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,116 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →